Susan K. Whoriskey, PhD
Biotechnology Executive, Technology Strategy & Business Development
Susan Whoriskey, PhD has served sequentially on the founding Executive Teams of four biotech companies: TruCode, Moderna (MRNA), Momenta Pharmaceuticals (MNTA) and Cubist Pharmaceuticals (CBST). TruCode is privately held. Moderna pioneered mRNA technology for drug development, is currently in Phase 3 clinical trials for a Covid-19 vaccine and has numerous other candidates in clinical trials to treat other diseases. Momenta received the first ever FDA approval for a generic version of a complex mixture drug while transitioning the application of its technology to novel drug development for unmet diseases and was sold to J & J in 2020 for $6.5B. Cubist received FDA approval for one of the first new classes of antibiotics approved by the FDA in 50 years to treat multi-drug resistant S. aureus and was sold to Merck in 2014 for $9.5B. As a member of the Executive Teams, Dr. Whoriskey played key roles in foundation setting, building teams, managing translation of academic inventions into therapeutic modalities, overseeing intellectual property strategy, completing venture capital financings, negotiating corporate partnerships, completing IPOs and follow-on financings and achieving four FDA drug approvals to date. She has been a consultant to Polaris Venture Partners and an Entrepreneur in Residence at MIT. Dr. Whoriskey earned her BS from UMass-Amherst and PhD from UCLA and was a Research Fellow in Molecular Genetics at Harvard Medical School with a Nobel Prize winner. She is an inventor on 50 patents & applications and a recipient of an Honorary Doctorate in Biotechnology and Entrepreneurism from the University of Ulster.